Pancreatic Cancer Therapeutics in Major Developed Markets: G17DT Expected to Rake in Highest Revenue by 2021

Published Date : Jan 06, 2016

Albany, New York, January 6, 2016: Pancreatic cancer, dreaded because of its characteristic rapid spread and asymptomatic nature when in its early stages, has created a massive global market for pancreatic cancer therapeutics. A new report now available on, studies the state of pancreatic therapeutics in major developed markets. The report is titled, ‘Pancreatic Cancer Therapeutics In Major Developed Markets To 2021 - Strong Late Stage Pipeline Holds Promise For Increasingly Diverse Market Landscape.’ Regional markets evaluated in the report include: The U.S., Canada, Germany, France, Italy, Japan, Spain, and the U.K.

The report states that pancreatic cancer is a disease that predominantly affects the aged, adding that approximately 75% of all pancreatic cases are diagnosed among those aged above 75 years. The fact that there is still a lack of early detection methods for pancreatic cancer makes early diagnosis doubly difficult. Oncologists’ preferred method to ensure patient survival is resection – a surgical method for which not all PC patients are eligible. Nevertheless, resection can help triple the survival rate of PC patients, taking the five-year survival rate 15% higher.

Unfortunately, a vast majority of patients are diagnosed with advanced unresectable pancreatic cancer. Most of these patients go on to develop a resistant form of the disease and hit a cul-de-sac in terms of treatment options, which have in any case been limited.

The treatment options available on the market entail fluorouracil as a monotherapy or the combination therapy. In what has come a ray of hope for patients with resistant form pancreatic cancer, the approval of Onivyde in 2015 for gemcitabine refractory disease has led to survival rates among such patients improving. Even so, the need to diversify the present treatment options continues to prevail.

The present report notes that the various late-stage pipeline drugs for pancreatic cancer will address this unmet need. Yet, it would be premature to say that these needs will be addressed effectively. The report states that trials of the late-stage drugs have failed to exhibit clinically transformative efficacy. Pancreatic cancer therapeutics in leading developed markets will thus still have enormous avenue for growth. The report expects factors such as an global aging population, an increasing prevalence of diabetes, and higher people suffering from obesity to contribute to the growth of the pancreatic cancer therapeutics market in developed countries.

For Sample Copy, click here:

The report also assesses the impact of drugs that are slated to receive approval during the forecast period of the report. These drugs include: TH-302, HyperAcute Pancreas, ruxolitinib phosphate, clivatuzumab tetraxetan, and G17DT. The authors of the report project that revenue from G17DT will be the highest, totaling an estimated US$141 mn by 2021.

To order report Call Toll Free: 866-997-4948 or send an email on